COMMUNIQUÉS West-GlobeNewswire

Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
30/07/2026
Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of [...]
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
30/07/2026
Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-001 + sacituzumab [...]
SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results
30/07/2026
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a [...]
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
30/07/2026
Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; trial will also inform WVE-007's potential in [...]
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
30/07/2026
STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling More than 70% of patients do not [...]
PharmAla Issues Q3 Financial Statements and AGM Update
30/07/2026
TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
30/07/2026
Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company [...]
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
30/07/2026
Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising FDA-approved drugs for repurposing, with the potential to accelerate patient access to effective therapies for [...]
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
30/07/2026
Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA) FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support [...]
Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic Telangiectasia
30/07/2026
Partnership with Cure HHT strengthens patient engagement and supports streamlined clinical trial execution Harmony-HHT Phase 1/2 trial activates first clinical site at Massachusetts General Hospital, marking an [...]
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
30/07/2026
Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities BOCA RATON, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio [...]
Relation unveils MORGAN, the next-generation model of cellular biology
30/07/2026
LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- Relation today announced MORGAN (Multi-Omic Regulatory Genomics using Artificial Neural Networks), our flagship cellular foundation model designed to transform how new biology [...]
Actimed Therapeutics Strengthens Board with Appointment of Dr. Anders Ullman
30/07/2026
London, UK – 30 July 2026. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting [...]
Relation Announces Expanded Collaboration with GSK
30/07/2026
Up to $110 million upfront and success-based milestones collaboration will generate large-scale human cellular perturbation datasets to advance understanding of disease biology LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- [...]
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa
30/07/2026
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa Nippon Shinyaku exercises its exclusive U.S. commercialization option for Tadekinig alfa after AB2 Bio’s [...]
Curium advances plans for second investment in Romania to expand access to advanced nuclear medicine
30/07/2026
Proposed expansion in the Cluj-Napoca region intended to strengthen PET imaging supply and support continued development of regional nuclear medicine services BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Curium™ announced [...]
Sugar Reset Drops Label Guide: What the Supplement Facts Panel, Serving Directions, and Safety Statements Disclose for 2026
30/07/2026
Sugar Reset Drops' Chromium Dose, Grapefruit and Licorice Interaction Details, and 20% Refund Fee Explained Largo, FL, July 30, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by the Food and Drug [...]
Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded
30/07/2026
Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded July 30, 2026 Q2 sales growth of 17.8% at CER 1 and business earnings per share (EPS) 2 of €2.09 Pharma launches sales increased [...]
Communiqué de presse : T2 2026 : croissance à deux chiffres du chiffre d’affaires et forte progression du BNPA ; révision à la hausse des perspectives 2026
30/07/2026
T2 2026 : croissance à deux chiffres du chiffre d’affaires et forte progression du BNPA ; révision à la hausse des perspectives 2026 Paris, le 30 juillet 2026 Ventes du T2 en progression de 17,8 % à TCC 1 et BNPA 2 des [...]

Pages